Polaryx Therapeutics Selects CRO for Soteria Clinical Trial
Polaryx Therapeutics announces it has selected a contract research organization, CRO, for Soteria, a phase 2, open-label, single-arm trial designed to evaluate the safety, tolerability, and clinical activity of Polaryx's lead candidate, PLX-200, across four different LSDs. "Our selection of a CRO partner marks an important milestone for us as we continue to advance the clinical development of SOTERIA and move closer to the clinic," said Lisa Bollinger, M.D., Chief Medical Officer of Polaryx Therapeutics, Inc. "Our new partner brings meaningful experience working with and managing LSD and rare pediatric trials, as well as deep-rooted relationships with the dedicated key opinion leaders and patient advocacy groups who work closely with patients and their families."
